Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225146 · ClinicalTrials.gov registry record · Phase 1
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
A Phase 1 study, sponsored by David M. Brown, M.D..
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01225146: Clinical Trial Phase 1 study, sponsored by David M. Brown, M.D..
NCT01225146 is a Phase 1 study that was terminated before completion, run by David M. Brown, M.D.. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01225146, a Phase 1 study, was terminated before completion, sponsored by David M. Brown, M.D..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
Primary Outcome
Mean change from baseline in ETDRS NCVA.
Interventions
- DRUG ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Why NCT01225146 stopped before completion
NCT01225146 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which ranibizumab is the first listed.
NCT01225146 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01225146 about?
NCT01225146 is a clinical study titled "Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)". The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
What is the current status of trial NCT01225146?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01225146?
The interventions under investigation include: ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01225146?
This trial is sponsored by David M. Brown, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01225146's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia